Arkade Developers shares rise 2% after company announces Rs 2,000 crore Thane project
By Aditya Bhagchandani Published on June 16, 2025, 09:24 IST
Shares of Arkade Developers Ltd rose over 2% to ₹195.50 in Monday's early trade after the company announced a strategic land acquisition in Thane. The Mumbai-based real estate company confirmed its foray into the Thane market with a 6.28-acre freehold land parcel at Kasarvadavali, Ghodbunder Road.
The company disclosed that the transaction, valued at ₹172.48 crore including stamp duty, is intended for a marquee mixed-use development with a projected gross development value (GDV) of ₹2,000 crore. The project is expected to offer 2, 3, and 4 BHK residences alongside curated retail and commercial spaces, with launch slated for early 2026.
The site offers sweeping views of the Sanjay Gandhi National Park and benefits from strong infrastructure connectivity via Eastern Express Highway and the upcoming Metro Line 4 and Thane-Borivali twin tunnel.
Arkade Developers Chairman & MD Amit Jain noted that the Thane expansion marks a major milestone in the company's growth, adding to recent developments in Kanjurmarg, Mulund, and Bhandup. The company also highlighted its recent acquisition of the 4-acre Filmistan land parcel in Goregaon with an estimated GDV of ₹3,000 crore.
As of the latest update, Arkade Developers shares were trading at ₹195.50, up 2.25% from the previous close of ₹191.20.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Ahmedabad Plane Crash
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
DoorDash purchases hospitality tech company SevenRooms
Online food ordering and delivery platform DoorDash has concluded the acquisition of the hospitality software provider SevenRooms. The US-based food delivery company states that the deal will bolster in-store sales, customer relationships and profitability for merchants by adding SevenRooms' CRM, reservations and guest experience tools to the DoorDash commerce platform. In May 2025, DoorDash agreed to acquire New York City-based SevenRooms for $1.2bn and UK competitor Deliveroo for £2.9bn ($3.8bn). SevenRooms will benefit from DoorDash's scale, resources and global reach. The company's leadership will join DoorDash to further develop its offerings. DoorDash vice-president of strategy and operations Parisa Sadrzadeh stated: 'We're building a platform that makes it easier for local businesses to grow — whether that's through delivery, pickup, reservations or in-person hospitality.' 'These capabilities reflect DoorDash's focus on empowering local businesses to deepen their relationships with customers, however they choose to connect - whether that's going out, ordering in or engaging through a merchant's own online stores. With SevenRooms, we will be able to keep supporting an open, partner-friendly ecosystem.' SevenRooms co-founder and head Joel Montaniel stated: 'We're excited to accelerate our mission to help hospitality operators around the world understand their guests, build deeper relationships and grow their businesses sustainably.' 'Together with DoorDash, we're providing restaurants and hospitality businesses with the tools to own their guest experience, grow their customer base and thrive both inside and outside their four walls. With shared core values, we're energised for our shared future as we bring continued innovation to market faster through a merchant-centric approach.' The acquisition comes shortly after DoorDash purchases ad tech startup Symbiosys for $175m, aimed at expanding its offsite advertising capabilities. Symbiosys offers a self-serve platform that allows advertisers to launch campaigns across channels including search, social, and display, while leveraging DoorDash's closed-loop measurement system. "DoorDash purchases hospitality tech company SevenRooms" was originally created and published by Verdict Food Service, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
41 minutes ago
- Yahoo
Almarai to buy bottled-water producer Pure Beverages
Saudi Arabian food and beverage group Almarai has agreed to acquire local bottled-water business Pure Beverages Industry Company for SR1.04 ($277m). In a stock-exchange filing yesterday (15 June), Almarai said the deal is in line with its 'growth strategy to expand its beverage portfolio and enhance its consumer offerings'. Almarai, which sells dairy and juice products under its namesake brand, added it is 'confident that this acquisition will create value for its shareholders'. Headquartered in Riyadh, Pure Beverages Industry Company owns the Ival and Oska brands, with factories in Riyadh, Jeddah and Dammam. According to its website, Pure Beverages Industry Company was set up by Saudi conglomerate Ajlan & Bros. Group in 1979. Almarai plans to finance the acquisition through its internal cash flows, with the completion of the transaction subject to contractual conditions and regulatory approvals in Saudi Arabia. The deal follows Almarai's recent unsuccessful attempt earlier this year to acquire Jordan-based Hammoudeh Food Industries. In March, Almarai said the deal could not proceed 'due to factors beyond the company's control, as the seller was unable to meet certain conditions required to complete the transaction'. Almarai added it is 'open to exploring future expansion opportunities, recognising the strategic importance of strengthening regional operations and expanding geographically to serve consumers in various markets'. The group operates in dairy, poultry, bakery, infant-nutrition, and juice sectors. In 2024, Almarai generated revenue of SR20.98bn, up from SR19.58bn in 2023. Operating profit stood at just under SR3bn, versus SR2.69bn a year earlier. Net profit was SR2.31bn, against SR2.05 the year previous. According to GlobalData, Just Drinks' parent, the size of Saudi Arabia's packaged water market in volume terms was 3.88bn litres last year. The data and analytics group forecasts growth of 3.9% this year to 4.03bn litres. In March, Berain Water, another Saudi bottled-water business, attracted a new investor. Hassana Investment Company acquired a 40% stake in Berain from Rajhi-Invest. Berain has three production plants in Jeddah and Riyadh, and markets bottled water in multiple size options. "Almarai to buy bottled-water producer Pure Beverages" was originally created and published by Just Drinks, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
43 minutes ago
- Yahoo
US pharma bets big on China to snap up potential blockbuster drugs
By Sriparna Roy and Sneha S K (Reuters) -U.S. drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data, betting they can turn upfront payments of as little as $80 million into multibillion-dollar treatments. Through June, U.S. drugmakers have signed 14 deals potentially worth $18.3 billion to license drugs from China-based companies. That compares with just two such deals in the year-earlier period, according to data from GlobalData provided exclusively to Reuters. That increased pace is expected to continue as U.S. drugmakers look to rebuild pipelines of future products to replace $200 billion worth of medicines that will lose patent protection by the end of the decade, analysts, investors, a banker and a drug company executive told Reuters. "They are finding very high-quality assets coming out of China and at prices that are much more affordable relative to perhaps the equivalent type of product that they might find in the United States," said Mizuho analyst Graig Suvannavejh. The total cost of licensing agreements, including low upfront payments and subsequent larger payouts, averaged $84.8 billion in the U.S., compared with $31.3 billion in China over the past five years, according to GlobalData. A licensing agreement grants a company the rights to develop, manufacture, and commercialize another company's pharmaceutical products or technologies in exchange for future target-based, or "milestone", payments while mitigating development risks. China's share of global drug development is now nearly 30%, while the U.S. share of the world's research and development has slipped 1% to about 48%, according to pharmaceutical data provider Citeline's report in March. Chinese companies have licensed experimental drugs to U.S. drugmakers that could be used for obesity, heart disease and cancer, reflecting abundant Chinese government investment in pharmaceutical and biotech research and development. While small molecules, like oral drugs, have been the most commonly licensed, there has been a notable shift toward novel treatments such as targeted cancer therapies and first-in-class medicines, Jefferies analysts said in a note in May. "Chinese biotechs are moving up the value chain by the day. They are... challenging their Western peers," said Macquarie Capital analyst Tony Ren. The growth is happening even as the U.S. and China have wrangled over tariffs and U.S. President Donald Trump pushes a made in America agenda. That has cut into traditional mergers and acquisitions, which are down 20%, with only 50 such transactions so far this year, according to data from database. Roughly a third of the assets that large pharmaceutical companies licensed in 2024 were from China, said Brian Gleason, head of biotech investment banking at Raymond James, who estimated such licensing deals would increase to between 40% and 50%. "I think it's only accelerating," Gleason said. The Trump administration is currently doing a national security investigation as it weighs if it will impose tariffs on the pharmaceutical sector. But one healthcare analyst said licensing deals should continue because the yet to be marketed products are not impacted by tariffs. "The law that gives the president the right to impose tariffs applies to goods. It explicitly excludes intellectual property," said Tim Opler, managing director in Stifel's global healthcare group. In May, Pfizer spent $1.25 billion upfront for the right to license an experimental cancer drug from China's 3SBio. That is the largest such deal this year and could be worth up to $6 billion in payments to 3SBio if the drug is successful. Regeneron Pharmaceuticals in June paid $80 million upfront in a potential $2 billion deal for an experimental obesity drug from China's Hansoh Pharmaceuticals. 'WAKEUP CALL' By licensing a drug in development, U.S. and European drugmakers get very quick access to a molecule which would take them longer and cost more to discover or design themselves, analysts say. U.S.-based drug developer Nuvation Bio bought AnHeart Therapeutics in 2024, gaining access to the China-based company's experimental cancer drug taletrectinib, which received U.S. approval last week. "We consider our presence in China not only a great avenue for R&D, but we also view it as an inside track on obtaining further assets to grow our company further and find new and better therapies to offer patients," Nuvation CEO David Hung told Reuters. What makes China attractive, said EY analyst Arda Ural, "a fraction of the cost and then multiples of time." Analysts have pointed to large drugmakers strategically securing rights to drugs at lower cost and running efficient early-stage trials in China to obtain important data, paving the way for global trials and potential earlier market entry. "It's a little bit of a wakeup call to our industry," said Chen Yu, Managing Partner at U.S.-based healthcare investment firm TCGX.
